Patient Guide: A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 0 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT07556549
Status: UPCOMING
Condition: Non-Small Cell Lung Cancer ALK-positive
Phase: Not Specified

Loading interactive enrollment tools...

The full interactive experience will load momentarily